EDSA

+ Watchlist + Portfolio

Edesa Biotech, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $5.75
52-Week Range: $0.72 – $20.32
Market Cap: $45.89M
P/E (TTM): —
EPS (TTM): -1.72
Dividend Yield: —

Advanced Metrics

Price/Book: 116.10
PEG Ratio: —
Return on Equity: -122.93%
Return on Assets: -66.43%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 2.76
Debt/Equity: —
Total Debt: $0.00
Free Cash Flow: $-5.12M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $53.52M

EDSA Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00	$0.00
Research & Development	$13.34M	$4.79M	$2.88M	$3.67M
Selling, General & Admin	$5.04M	$4.43M	$4.13M	$4.24M
Operating Expenses	$17.59M	$8.64M	$6.32M	$7.13M
Operating Income	-$17.59M	-$8.64M	-$6.32M	-$7.13M
EBITDA	-$17.47M	-$8.46M	-$6.13M	-$7.01M
Pretax Income	-$17.55M	-$8.37M	-$6.17M	-$7.18M
Income Tax	$800.00	$800.00	$800.00	$800.00
Net Income	-$17.55M	-$8.37M	-$6.17M	-$7.19M
Diluted EPS	-7.35	-2.93	-1.93	-1.27
Diluted Shares	2.38M	2.86M	3.20M	5.68M

EDSA Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$7.09M	$5.36M	$1.04M	$10.79M
Receivables	$1.26M	$626.54K	$270.91K	$642.87K
Current Assets	$9.09M	$6.44M	$1.68M	$11.51M
Total Assets	$11.58M	$8.89M	$3.81M	$13.53M
Current Liabilities	$2.14M	$1.82M	$1.83M	$1.08M
Total Debt	$18.98K	$94.49K	$19.87K	$0.00
Total Liabilities	$2.18M	$1.84M	$1.83M	$1.08M
Retained Earnings	-$44.04M	-$52.42M	-$58.59M	-$65.91M
Shareholders' Equity	$9.39M	$7.05M	$1.98M	$12.45M
Working Capital	$6.95M	$4.61M	-$157.21K	$10.43M

EDSA Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$12.28M	-$6.64M	-$4.89M	-$7.32M
Capital Expenditure	-$5.66K	—	—	—
Free Cash Flow	-$12.28M	-$6.64M	-$4.89M	-$7.32M
Depreciation & Amortisation	$118.19K	$183.47K	$186.05K	$119.27K
Stock-Based Compensation	$2.26M	$1.25M	$537.49K	$729.64K
Investing Cash Flow	-$5.66K	$0.00	—	—
Financing Cash Flow	$11.63M	$4.83M	$592.03K	$17.03M
Net Change in Cash	-$655.33K	-$1.81M	-$4.30M	$9.71M

EDSA Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$484.31K	$939.07K	$1.23M	$1.12M	$2.77M
Selling, General & Admin	$1.15M	$964.68K	$1.24M	$1.22M	$1.53M
Operating Expenses	$1.59M	$1.72M	$2.22M	$2.24M	$4.23M
Operating Income	-$1.59M	-$1.72M	-$2.22M	-$2.24M	-$4.23M
EBITDA	-$1.56M	-$1.69M	-$2.20M	-$2.21M	-$4.20M
Pretax Income	-$1.59M	-$1.75M	-$2.23M	-$2.25M	-$4.22M
Income Tax	$800.00	$0.00	$0.00	—	$800.00
Net Income	-$1.59M	-$1.75M	-$2.23M	-$2.25M	-$4.22M
Diluted EPS	-0.30	-0.25	—	-0.28	-0.49
Diluted Shares	5.31M	7.02M	—	7.97M	8.54M

EDSA Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$13.90M	$12.36M	$10.79M	$12.05M	$10.00M
Receivables	$382.44K	$286.74K	$642.87K	$431.32K	$216.47K
Current Assets	$14.39M	$12.76M	$11.51M	$12.72M	$10.42M
Total Assets	$16.45M	$14.80M	$13.53M	$14.71M	$12.38M
Current Liabilities	$914.70K	$672.67K	$1.08M	$756.16K	$2.19M
Total Debt	$0.00	$0.00	$0.00	—	—
Total Liabilities	$914.70K	$672.67K	$1.08M	$756.16K	$2.19M
Retained Earnings	-$61.86M	-$63.65M	-$65.91M	-$68.20M	-$72.45M
Shareholders' Equity	$15.54M	$14.13M	$12.45M	$13.95M	$10.20M
Working Capital	$13.47M	$12.09M	$10.43M	$11.96M	$8.23M

EDSA Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$2.38M	-$1.70M	-$1.72M	-$2.09M	-$2.02M
Free Cash Flow	-$2.38M	-$1.70M	-$1.72M	-$2.09M	-$2.02M
Depreciation & Amortisation	$24.51K	$25.79K	$25.87K	$25.46K	$25.87K
Stock-Based Compensation	$66.65K	$177.38K	$404.43K	$399.86K	$484.85K
Financing Cash Flow	$14.77M	$0.00	$186.48K	$3.36M	-$8.98K
Net Change in Cash	$12.39M	-$1.70M	-$1.53M	$1.27M	-$2.03M

Market Snapshot

About

Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics for inflammatory and immune-related diseases. The company's lead product candidate, EB05, is being investigated for acute respiratory distress syndrome and other conditions involving excessive inflammation. Edesa is also developing dermatology treatments and other antibody-based therapies targeting unmet medical needs. Headquartered in Ontario, Canada, the company focuses on repurposing and advancing novel applications of antibody platforms through clinical development.